Exane Derivatives’s GSK GSK Stock Holding History

Exane Derivatives’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-530	Closed	-$1.12K	–	692
2018 Q4	$1.12K	Sell	530 -764	-59%	-$37.6K	﹤0.01%	564
2018 Q3	$34.2K	Buy	1,294 +77	+6%	+$3.91K	0.01%	388
2018 Q2	$43.3K	Buy	1,217 +409	+51%	+$20.6K	0.01%	397
2018 Q1	$194K	Sell	808 -40	-5%	-$1.86K	0.04%	241
2017 Q4	$48.7K	Buy	+848	New	+$39.2K	0.01%	341
2017 Q3	–	Sell	-7	Closed	-$180	–	604
2017 Q2	$180	Sell	7 -2	-22%	-$107	﹤0.01%	544
2017 Q1	$335	Buy	+9	New	+$457	﹤0.01%	446
2016 Q4	–	Sell	-162	Closed	-$4.67K	–	667
2016 Q3	$4.67K	Buy	+162	New	+$8.88K	﹤0.01%	445
2016 Q1	–	Sell	-7	Closed	-$45	–	602
2015 Q4	$45	Sell	7 -56	-89%	-$2.85K	﹤0.01%	473
2015 Q3	$943	Buy	+63	New	+$3.28K	﹤0.01%	431
2015 Q1	–	Sell	-41	Closed	-$155	–	538
2014 Q4	$155	Buy	+41	New	+$2.29K	﹤0.01%	498

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

BCIM

Black Creek Investment Management Toronto, Ontario, Canada $1.86B AUM 15.33% 1-Year Est. Return

Exane Derivatives's GSK Position: Q1 2019 in Review

Exane Derivatives sold out of GSK (GSK) in Q1 2019, closing a stake of 15,440 shares — an estimated $737K sold.

Exane Derivatives first reported a position in GSK in Q4 2014 and held it in 6 quarters. The position peaked at $737K in Q4 2018. 847 funds tracked by Wall St. Rank hold GSK as of Q1 2019.

Exane Derivatives reported no remaining GSK position as of Q1 2019 after selling out during the quarter.
Exane Derivatives sold 15,440 GSK shares in Q1 2019, an estimated $737K.
Exane Derivatives first reported a position in GSK in Q4 2014 and held it in 6 quarters.
Exane Derivatives's GSK position peaked at $737K in Q4 2018.
847 funds tracked by Wall St. Rank held GSK as of Q1 2019.

Based on Exane Derivatives's 13F filing for Q1 2019, filed 24 Apr 2019.